| Biomarker ID | 830 |
| PMID | 22175903 |
| Year | 2011 |
| Biomarker | Secreted frizzled-related protein (SFRP)-2 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Gleason Grade 5 (PCa: 3.16 ± 0.99; Control: 0.77±0.15) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Wnt signaling pathway |
| Experiment | Gleason Grade 3,4 Vs Gleason Grade 5 |
| Type of Biomarker | Prognostic |
| Cohort | 216 patients with Prostate cancer and 37 controls (with Benign Prostatic Hyperplasia) were chosen for the study, |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Results verified on rna (pcr) but not found significant |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SFRP2 |